<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4156">
  <stage>Registered</stage>
  <submitdate>26/08/2013</submitdate>
  <approvaldate>26/08/2013</approvaldate>
  <nctid>NCT01931566</nctid>
  <trial_identification>
    <studytitle>Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset</studytitle>
    <scientifictitle>A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects</scientifictitle>
    <utrn />
    <trialacronym>TOMMORROW</trialacronym>
    <secondaryid>2012-003111-58</secondaryid>
    <secondaryid>AD-4833/TOMM40_301</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Mild Cognitive Impairment Due to Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Pioglitazone
Treatment: drugs - Pioglitazone placebo

Experimental: Pioglitazone - Pioglitazone tablets, orally, once daily for up to 5 years.

Placebo Comparator: Placebo - Pioglitazone placebo-matching tablets, orally, once daily for up to 5 years.


Treatment: drugs: Pioglitazone
Low-Dose Pioglitazone tablets

Treatment: drugs: Pioglitazone placebo
Pioglitazone placebo-matching tablets

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to diagnosis of Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD) for placebo-treated, high-risk, non-Hispanic/Latino Caucasian subjects versus placebo-treated, low-risk, non-Hispanic/Latino Caucasian subjects - A test from a Cox proportional hazards survival model will be used to compare data from non-Hispanic/Latino Caucasians in the (placebo-treated) low-risk group (ie, the combined placebo groups) with data from non-Hispanic/Latino Caucasians in the placebo-treated subjects in the high-risk group. The event in this analysis will be the diagnosis of cognitive impairment. If this test is significant at the 0.01 level, it can be concluded that the diagnostic prognostic test has differentiated between subjects at low and high risk of being diagnosed with cognitive impairment within 5 years of taking the test.</outcome>
      <timepoint>Baseline to end of study, anticipated to be about 5 years.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Time to diagnosis of MCI due to AD for pioglitazone-treated, non-Hispanic/Latino Caucasian subjects versus placebo-treated non-Hispanic/Latino, Caucasian subjects in the high-risk stratum - A test from a Cox proportional hazards survival model will be used to compare data from non-Hispanic/Latino Caucasians in the (placebo-treated) low-risk group (ie, the combined placebo groups) with data from non-Hispanic/Latino Caucasians in the placebo-treated subjects in the high-risk group. The event in this analysis will be the diagnosis of cognitive impairment. If this test is significant at the 0.01 level, it can be concluded that the diagnostic prognostic test has differentiated between subjects at low and high risk of being diagnosed with cognitive impairment within 5 years of taking the test.
If this test is significant at the 0.01 level, it can be concluded that active treatment has delayed the development of cognitive impairment within the 5-year period.</outcome>
      <timepoint>Baseline to end of study, anticipated to be about 5 years.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline for cognitive decline on composite score on the cognitive test battery for pioglitazone-treated subjects versus placebo-treated subjects in the high-risk stratum - Composite scores will be derived from the test battery. Only the domains of episodic memory, executive function, language, and attention will be used for the composite score. To form the composite, z-scores will be calculated for each test, each z-score for the domain will be averaged, and then all relevant domains will be averaged to form the composite.</outcome>
      <timepoint>Baseline and months 6, 12, 18, 24, 30, 36, 42 and 48</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from baseline in instrumental activities of daily living (Alzheimer's Disease Cooperative Study Activities of Daily Living - Prevention Instrument [ADCS ADL-PI]) between pioglitazone-treated and placebo-treated groups of the high-risk stratum - Self assessment of memory function will be obtained using the ADCS Prevention Instrument Project- Mail In Cognitive Function Screening Instrument. This is a 14-item self administered yes/no questionnaire to assess recent changes (over the last year) in cognition and functional activities which commonly are affected in the development of MCI.</outcome>
      <timepoint>Baseline and months 6, 12, 18, 24, 30, 36, 42 and 48</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. In the opinion of the investigator, participant is capable of understanding and
             complying with protocol requirements.

          2. Signs and dates a written, informed consent form and any required privacy
             authorization prior to the initiation of any study procedures.

          3. Is able to physically perform the cognitive tests in the opinion of the investigator
             and is fluent in the language that tests will be administered.

          4. Is cognitively normal at baseline, scoring as indicated for the following tests:

               -  Clinical Dementia Rating (CDR)=0.

               -  At least one memory test above -1.5 stanard deviation (SD) of the demographically
                  corrected normative mean.

          5. Must score =25 on the Mini-Mental State Examination (MMSE) at the screening visit
             after the education and age adjustment.

          6. Is male or postmenopausal female between the ages of 65 and 83 years, inclusive, at
             time of the Screening visit.

          7. Has the ability and intention to participate in regular study visits, in the opinion
             of the Investigator.

          8. Has a project partner who can separately complete an Acknowledgement Form on his/her
             own behalf and take part in the study (with the intent to do so as long as the
             participant is enrolled) to provide information on the cognitive, functional, and
             behavioral status of the participant and to assist with monitoring of study
             medication, if needed.</inclusivecriteria>
    <inclusiveminage>65</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>83</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Has a current diagnosis or history of any type of cognitive impairment or dementia, or
             has a current diagnosis or history of neurological/psychiatric disorder or any other
             diagnosis that significantly affects cognitive performance (eg, mental retardation,
             organic mental disorder).

          2. Has a current diagnosis of significant psychiatric illness, per Diagnostic &amp;
             Statistical Manual of Mental Disorders, 4th Edition - Text Revision (DSM-IV-TR) (or
             DSM-V when published) (including but not limited to major depressive disorder, anxiety
             disorders) and is in an acute phase/episode, or the participant has a current
             diagnosis or history of schizophrenia or bipolar disorder.

          3. Has a glycosylated hemoglobin (HbA1c) &gt;8.0% at the time of baseline or requires
             treatment with insulin, triple oral antidiabetic therapy or a peroxisome
             proliferator-activated receptor-gamma (PPAR-?) agonist. The participant should be on a
             stable antidiabetic regimen for at least 3 months prior to enrollment.

          4. Has a clinically significant unstable illness, for example, hepatic impairment or
             renal insufficiency, or cardiovascular, pulmonary, gastrointestinal (including s/p
             gastric bypass), endocrine, neurological, rheumatologic, immunologic, infectious, skin
             and subcutaneous tissue disorders, or metabolic disturbance. History of HIV infection
             is considered exclusionary for this study.

          5. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse/dependence within 2 years prior to the Screening Visit.

          6. Is an immediate family member, testing center employee, or is in a dependent
             relationship with a testing center employee who is involved in conduct of this study
             (eg, spouse, parent, child, and sibling) or may consent under duress.

          7. Has a history of hypersensitivity or allergies to pioglitazone or related compounds.

          8. Is required to take excluded medications as specified in the Excluded Medications
             Section.

          9. Had any of the following values at the Baseline Visit (Visit 2):

               1. A serum total bilirubin value &gt;1.5Ã— upper limit of normal (ULN).

               2. A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value
                  &gt;2xULN.

               3. Unexplained microscopic/macroscopic hematuria on one repeat examinations within 2
                  weeks of the initial assessment.

         10. Is positive for either Hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus
             (HCV) antibodies at the Baseline Visit (Visit 2).

         11. Has a condition or takes medication that, in the opinion of the Investigator, could
             interfer with the assessments of safety, tolerability, or efficacy, or prevent the
             participant from adequately participating in the study or continue for the anticipated
             duration of the study.

         12. Has received any investigational compound within 30 days prior to screening or 5
             half-lives prior to Screening or is currently participating in another study which
             entails the administration of an investigational or marketed drug, supplement or
             intervention including, but not limited to diet, exercise, lifestyle or invasive
             procedure.

         13. Has a history of any cancer that has been in remission for less than 2 years from the
             Screening Visit. Participants with basal cell or stage I squamous cell carcinoma of
             the skin will be eligible. Participants with history of bladder cancer are not
             eligible irrespective of the remission status.

         14. Has a history or current diagnosis of macular edema or macular degeneration.

         15. If female, has a history of postmenopausal fractures with no or minimal trauma (eg,
             wrist, hip, lumbar or thoracic vertebral fracture).

         16. Has a history or current diagnosis of congestive heart failure (CHF), New York Heart
             Association Class III-IV.

         17. Has been exposed to the cognitive tests performed in this study within 6 months prior
             to the Screening Visit, with the exception of the MMSE.

         18. Participant's Translocase of the Outer Mitochondrial Membrane 40 homolog (TOMM40)
             rs10524523 or apolipoprotein E (APOE) genotypes or APOE phenotype are known by the
             participant or the study staff participating in this study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>3494</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital> - North Ryde</hospital>
    <hospital> - Southport</hospital>
    <hospital> - West Heidelberg</hospital>
    <hospital> - Nedlands</hospital>
    <postcode> - North Ryde</postcode>
    <postcode> - Southport</postcode>
    <postcode> - West Heidelberg</postcode>
    <postcode> - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Baden Wuerttemberg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen Anhalt</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Devon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Greater Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Middlesex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Strathclyde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Tayside Region</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Takeda</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Zinfandel Pharmaceuticals Inc.</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the
      risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to
      evaluate the efficacy of pioglitazone compared with placebo to delay the onset of MCI-AD in
      cognitively-normal participants who are at high-risk for developing MCI within 5 years.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01931566</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Director</name>
      <address>Takeda</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>